Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY500307 for LUTS/BPH
NCT01097707Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of erteberel in benign prostatic hyperplasia (BPH), sponsored by Eli Lilly and Company. Started Apr 2010; status: terminated.
02
Drugs
erteberel
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT01097707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01097707.